Volume 11 Supplement 5

Severe sepsis and drotrecogin alfa (activated)


Edited by Antonio Artigas and Claude D Martin

Publication of the supplement has been sponsored by Eli Lilly & Company

  1. Review

    Diagnosis and treatment of severe sepsis

    The burden of infection in industrialized countries has prompted considerable effort to improve the outcomes of patients with sepsis. This has been formalized through the Surviving Sepsis Campaign 'bundles', d...

    Yann-Erick Claessens and Jean-Fran├žois Dhainaut

    Critical Care 2007 11(Suppl 5):S2

    Published on: 19 December 2007

  2. Review

    The protein C pathway: implications for the design of the RESPOND study

    The predictive value of plasma protein C level in sepsis has been demonstrated in a number of studies in which depressed protein C levels were associated with increased likelihood of negative outcome. Data fro...

    Burkhard Vangerow, Andrew F Shorr, Duncan Wyncoll, Jonathan Janes, David R Nelson and Konrad Reinhart

    Critical Care 2007 11(Suppl 5):S4

    Published on: 19 December 2007

  3. Review

    Clinical trials in severe sepsis with drotrecogin alfa (activated)

    Drotecogin alfa (activated; DrotAA) was approved in 2001 by the US Food and Drug Administration for the treatment of patients with severe sepsis who are at high risk for death. The European Agency for the Eval...

    Pierre-Fran├žois Laterre

    Critical Care 2007 11(Suppl 5):S5

    Published on: 19 December 2007

  4. Review

    The safety profile of drotrecogin alfa (activated)

    Continued safety assessment is essential for any newly approved therapy. Drotrecogin alfa (activated; DrotAA), which is approved for use in severe sepsis, has undergone clinical trials with corresponding safet...

    Roberto Fumagalli and Mariano A Mignini

    Critical Care 2007 11(Suppl 5):S6

    Published on: 19 December 2007

  5. Review

    Practical aspects of treatment with drotrecogin alfa (activated)

    In November 2001, drotrecogin alfa (activated) was approved by the US Food and Drug Administration; in August 2002 it was approved by the European Medicines Agency. Since the approval of drotrecogin alfa (acti...

    Luigi Camporota and Duncan Wyncoll

    Critical Care 2007 11(Suppl 5):S7

    Published on: 19 December 2007